Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06679270 · ClinicalTrials.gov registry record · Phase 3
Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy
A Phase 3 study of Familial Partial Lipodystrophy, sponsored by Amryt Pharma.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 24
- Enrollment target
- 7
- Study locations
NCT06679270: Recruiting Phase 3 study of Familial Partial Lipodystrophy, sponsored by Amryt Pharma.
NCT06679270 is a Phase 3 study of Familial Partial Lipodystrophy that is actively recruiting participants, run by Amryt Pharma. The registered enrollment target is 24 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06679270, a Phase 3 study of Familial Partial Lipodystrophy, is actively recruiting participants, sponsored by Amryt Pharma.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 24 participants
- Enrollment target
- 7
- Study locations
Study Summary
This Phase 3 study is an Open Label Extension of the APG-20 Study To Evaluate the Long-term Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with Partial Lipodystrophy
Primary Outcome
Incidence and frequency of treatment-emergent adverse events (TEAEs) including serious adverse events (SAEs), treatment-related TEAEs, adverse events of special interest (AESI), and adverse events leading to study treatment discontinuation/withdrawal from the study
Conditions Studied
Interventions
- DRUG Metreleptin
Study Locations (7)
Alabama
- University of Alabama - Birmingham
Florida
- Flourish Research - Boca Raton
Massachusetts
- Massachusetts General Hospital - Boston
Michigan
- University of Michigan - Ann Arbour
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Texas
- UT Southwestern Medical Center - Dallas
Wisconsin
- The Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-10-14 |
| Est. Completion | 2028-12 |
| Phase | Phase 3 |
What NCT06679270 shows while recruiting
NCT06679270 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Familial Partial Lipodystrophy appearing as the primary indexed condition, and to 1 intervention - of which Metreleptin is the first listed.
NCT06679270 lists 7 locations in 7 states (Alabama, Florida, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT06679270 about?
NCT06679270 is a clinical study titled "Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy". This Phase 3 study is an Open Label Extension of the APG-20 Study To Evaluate the Long-term Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with Partial Lipodystrophy
What is the current status of trial NCT06679270?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 24 participants. The study started on 2024-10-14. Estimated completion is 2028-12.
What conditions does trial NCT06679270 study?
This clinical trial studies the following conditions: Familial Partial Lipodystrophy.
What interventions are being tested in trial NCT06679270?
The interventions under investigation include: Metreleptin (DRUG).
Who is sponsoring clinical trial NCT06679270?
This trial is sponsored by Amryt Pharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06679270 being conducted?
This trial has 7 study locations across Alabama, Florida, Massachusetts, Michigan, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Familial Partial Lipodystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06679270's enrollment target sits among peer trials
24 1944th of 2000 higher than 49 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI